The evolving role of receptors as predictive biomarkers for metastatic breast cancer.

Abstract:

INTRODUCTION:In breast cancer, estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) are essential biomarkers to predict response to endocrine and anti-HER2 therapies, respectively. In metastatic breast cancer, the use of these receptors and targeted therapies present additional challenges: temporal heterogeneity, together with limited sampling methodologies, hinders receptor status assessment, and the constant evolution of the disease invariably leads to resistance to treatment. Areas covered: This review summarizes the genomic abnormalities in ER and HER2, such as mutations, amplifications, translocations, and alternative splicing, emerging as novel biomarkers that provide an insight into underlying mechanisms of resistance and hold potential predictive value to inform treatment selection. We also describe how liquid biopsies for sampling of circulating markers and ultrasensitive detection technologies have emerged which complement ongoing efforts for biomarker discovery and analysis. Expert commentary: While evidence suggests that genomic aberrations in ER and HER2 could contribute to meeting the pressing need for better predictive biomarkers, efforts need to be made to standardize assessment methods and better understand the resistance mechanisms these markers denote. Taking advantage of emerging technologies, research in upcoming years should include prospective trials incorporating these predictors into the study design to validate their potential clinical value.

authors

Martínez-Pérez C,Turnbull AK,Dixon JM

doi

10.1080/14737140.2019.1552138

subject

Has Abstract

pub_date

2019-02-01 00:00:00

pages

121-138

issue

2

eissn

1473-7140

issn

1744-8328

journal_volume

19

pub_type

杂志文章,评审
  • Early outcomes data for accelerated partial breast irradiation using balloon brachytherapy.

    abstract::Accelerated partial breast irradiation has been investigated in selected patients with early-stage breast cancer. Accelerated partial breast irradiation limits the radiation target to the volume of tissue immediately surrounding the lumpectomy cavity and reduces the overall treatment time from approximately 6 weeks to...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.113

    authors: Cuttino LW,Vicini FA

    更新日期:2011-09-01 00:00:00

  • Adopting an alternative structure for clinical trials in immunotherapy.

    abstract::Background: This evaluation emphasizes the main points of the original article 'Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies' by Sprenger et al. and provides further justification for the use of an alternative approach in the design...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1875822

    authors: Roussos Torres ET,Epstein AL

    更新日期:2021-01-19 00:00:00

  • Individualized cancer therapy: molecular approaches to the prediction of tumor response.

    abstract::A major issue with current cancer therapy is how to ensure the maximum benefit with minimum toxicity for individual patients. With the progress of the human genome project have come high-throughput technologies for the analysis of DNA, gene expression or tumor protein in an efficient and quantitative manner. This revi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2.1.113

    authors: McLeod HL

    更新日期:2002-02-01 00:00:00

  • Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer.

    abstract::Endothelin axis deregulation triggers a series of events that ultimately activate proliferation, invasion, escape from programmed cell death, new vessel formation, abnormal osteogenesis and alteration of nociceptive stimuli. Atrasentan is a novel agent that effectively targets this pathway and is able to inhibit and/o...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.3.419

    authors: Jimeno A,Carducci M

    更新日期:2005-06-01 00:00:00

  • Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.

    abstract::Although the general intent of treatment for patients with recurrent ovarian cancer is palliative, and cure does not seem to be a realistic objective in this setting, median overall survival is greater than 12 months in platinum-sensitive recurrent ovarian cancer. Patients with ovarian cancer can now expect that the t...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.3.437

    authors: Kose MF,Meydanli MM,Tulunay G

    更新日期:2006-03-01 00:00:00

  • The influence of pH and hypoxia on tumor metastasis.

    abstract::Rapid malignant proliferation, prior to effective tumor neoangiogenesis, creates a microenvironment around solid cancers, which is predominantly hypoxic and characterized by a high interstitial fluid pressure. Presumably as an adaptive response, tumor cells favor metabolic activity with apparently inefficient energy o...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.843455

    authors: Abaza M,Luqmani YA

    更新日期:2013-10-01 00:00:00

  • Advances in radiation therapy of head and neck cancer.

    abstract::Head and neck cancer is the fifth most common cancer in the USA. Although there have been major improvements in surgical and radiation techniques, the overall survival has not changed significantly in the last decade. The major changes occurring in recent years have been in the ability to preserve organs and to improv...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.4.633

    authors: Popovtzer A,Eisbruch A

    更新日期:2008-04-01 00:00:00

  • Is axillary dissection needed in node-positive breast cancer?

    abstract::The standard of care in the management of the axilla for a woman with breast cancer was traditionally a level I and II axillary lymph node dissection (ALND). Since the pivotal studies in the mid-1990s, sentinel lymph node biopsy (SLNB) in breast carcinoma has come to replace ALND in women with clinically negative axil...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.8.2.195

    authors: Greenberg CC,Bafford AC,Golshan M

    更新日期:2008-02-01 00:00:00

  • Emerging agents for the treatment of mantle cell lymphoma.

    abstract::The characterization of the mantle cell lymphoma (MCL) entity had a major impact on patient management and has played a profound role in improving therapy. Although the prognosis is improving in MCL, there is no definitive proof that the therapies currently available will lead to cure. Few randomized studies have been...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.99

    authors: Camara-Clayette V,Hermine O,Ribrag V

    更新日期:2012-09-01 00:00:00

  • Capecitabine in the treatment of colorectal cancer.

    abstract::Capecitabine is an oral prodrug of 5-fluorouracil. It is being increasingly used in the treatment of colorectal cancer in both the adjuvant and metastatic settings. This review aims to explore the data in relation to the pharmacology and mode of action of capecitabine, followed by an in-depth review of the available c...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.6.803

    authors: Kelly C,Cassidy J

    更新日期:2007-06-01 00:00:00

  • Management of long bone metastases: recommendations from the Italian Orthopaedic Society bone metastasis study group.

    abstract::The purpose of this article is to outline the current approach to patients affected by metastasis to the long bones and to present a clinical and surgical algorithm available for clinicians and for future research. A modern approach to patients affected by long bone metastasis in fact requires a multidisciplinary cont...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.2014.947691

    authors: Capanna R,Piccioli A,Di Martino A,Daolio PA,Ippolito V,Maccauro G,Piana R,Ruggieri P,Gasbarrini A,Spinelli MS,Campanacci DA,Italian Orthopaedic Society Bone Metastasis Study Group.

    更新日期:2014-10-01 00:00:00

  • Personalized medical treatment strategies for patients with chronic myeloid leukemia.

    abstract::Management of patients with chronic myeloid leukemia has become increasingly difficult over the last few years since there are a variety of treatment options available. The ultimate challenge is to decide the most appropriate treatment strategy for an individual patient. To facilitate this, assessment of an individual...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.2.343

    authors: Burton C,Marin D,Apperley J

    更新日期:2005-04-01 00:00:00

  • The role of surgery in recurrent endometrial cancer.

    abstract:INTRODUCTION:Endometrial cancer is a common gynecologic malignancy in the United States, and the recurrence rate depends on the disease stage at diagnosis. Recurrence can affect several areas and follow different patterns. AREAS COVERED:The role of surgery at the time of recurrence is not clearly defined. In this revi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2016.1190650

    authors: Zanfagnin V,Ferrero A,Biglia N,Aletti G,Gill SE,Makdisi PB,Multinu F,Mariani A

    更新日期:2016-07-01 00:00:00

  • Predicting survival in chronic lymphocytic leukemia.

    abstract::There is increasing interest in the use of prognostic markers that may predict survival and guide management in patients diagnosed with the early stages of chronic lymphocytic leukemia (CLL). Currently, the most important traditional prognostic factors include clinical staging, lymphocyte doubling time and β2-microglo...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.2

    authors: Bazargan A,Tam CS,Keating MJ

    更新日期:2012-03-01 00:00:00

  • Emerging personalized approaches for the management of advanced urothelial carcinoma.

    abstract::Urothelial carcinoma of the bladder comprises a spectrum of illnesses ranging from nonmuscle-invasive to muscle-invasive to advanced/metastatic disease. Each of these clinical states is characterized by a unique pathogenesis, prognosis and approach to treatment. However, given the heterogeneity of urothelial carcinoma...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.141

    authors: Tsao CK,Gartrell BA,Oh WK,Galsky MD

    更新日期:2012-12-01 00:00:00

  • Clodronate in the prevention and treatment of skeletal metastasis.

    abstract::Many solid tumors, including breast and prostate cancer, metastasize to bone, thereby putting patients at high risk for developing skeletal complications including pathologic fracture, spinal cord compression and debilitating bone pain. Patients often live for many years after developing bone metastasis, a fact that h...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.2.221

    authors: Gulley J,Dahut WL

    更新日期:2005-04-01 00:00:00

  • Colorectal cancer stem cells and their implications for novel anticancer therapy.

    abstract::Anticancer therapy relies on targeting highly proliferative cells. Commonly used chemotherapy does not selectively target individual cancer cells. The identification of distinct cancer stem cells that have the unique ability to engraft tumors and maintain cancer self-renewal may prove vital in the development of novel...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.13.17

    authors: Klotz D

    更新日期:2013-04-01 00:00:00

  • Metastases of colorectal cancer to the liver and peritoneum: comparison of surgical paradigms.

    abstract::The treatment of metastatic colorectal cancer is evolving. Although the advent of new chemotherapeutic and biologic agents has certainly improved the outlook for many patients, surgical resection in certain subsets of patients with advanced colorectal cancer is the only chance for long-term survival. Traditionally, pa...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.11.1797

    authors: Shen P,Stewart JH,Levine EA

    更新日期:2008-11-01 00:00:00

  • Invadopodia: a new therapeutic target to block cancer metastasis.

    abstract::Cancer cells become dangerous when they acquire the ability to invade through physical barriers in the body and disseminate to distant sites. Recent evidence has demonstrated that cancer cells utilize specialized structures called invadopodia, unique protrusions that concentrate proteases such as matrix metalloprotein...

    journal_title:Expert review of anticancer therapy

    pub_type: 社论

    doi:10.1586/14737140.2015.1058711

    authors: Stoletov K,Lewis JD

    更新日期:2015-01-01 00:00:00

  • Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.

    abstract::Nonseminomatous germ cell tumors of the testicle are highly treatable and curable. The evolution of cancer control for this disease has demonstrated an effective integration of medical and surgical approaches over the last 30 years. Current emphasis in the therapy of nonseminomatous germ cell tumors focuses on minimiz...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.1.75

    authors: Yoon GH,Stein JP,Skinner DG

    更新日期:2005-02-01 00:00:00

  • Antiangiogenic therapies: is VEGF-A inhibition alone enough?

    abstract::Although available targeted therapies provide some clinical efficacy, a need remains for antiangiogenic therapies with alternative mechanisms in order to provide better outcomes and the ability to circumvent resistance. Inhibition of multiple VEGF targets may produce enhanced efficacy and more durable responses throug...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/era.11.5

    authors: Gordon MS

    更新日期:2011-03-01 00:00:00

  • Contralateral prophylactic mastectomy for patients with unilateral breast cancer.

    abstract::Patients with unilateral breast cancer are at increased risk of developing a second cancer in the contralateral breast. Some women choose contralateral prophylactic mastectomy (CPM) to prevent cancer in the contralateral breast. Several studies have demonstrated that CPM significantly decreases the occurrence of contr...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.8.1117

    authors: Tuttle T,Habermann E,Abraham A,Emory T,Virnig B

    更新日期:2007-08-01 00:00:00

  • IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.

    abstract::Tamoxifen has been shown to reduce the incidence of estrogen receptor-positive breast cancer by approximately 50% in high-risk women. Similar results are seen for raloxifene, but it has a more favorable side-effect profile. Data on contralateral tumors from women in adjuvant trials treated with aromatase inhibitors su...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.8.9.1377

    authors: Cuzick J

    更新日期:2008-09-01 00:00:00

  • Emerging data on improving response to hormone therapy: the role of novel targeted agents.

    abstract:INTRODUCTION:Hormone receptor positive (HR+) breast cancer represents the most common subtype of breast cancer. Metastatic HR+ breast cancer may develop resistance to standard hormone therapies, arising from genomic alterations in the estrogen receptor and/or upregulation of other signal transduction pathways. Areas co...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1412259

    authors: Vidula N,Rugo HS

    更新日期:2018-01-01 00:00:00

  • Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.

    abstract::Tumors of the CNS frequently have devastating consequences in terms of cognitive and motor function, personality and mortality. Despite decades of work, current therapies have done little to alter the course of these deadly diseases. The discovery that chaperones/heat-shock proteins play an important role in tumor bio...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.6.5.679

    authors: Graner MW,Bigner DD

    更新日期:2006-05-01 00:00:00

  • Management of residual masses in testicular germ cell tumors.

    abstract:INTRODUCTION:About 50% of all patients with advanced testicular cancer demonstrate residual retroperitoneal or extraretroperitoneal masses. About two thirds of the masses harbour necrosis/fibrosis only whereas as about 10% and 40% harbour vital cancer or teratoma. Appropriate therapy will result in a high cure rate if ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2019.1580146

    authors: Heidenreich A,Paffenholz P,Nestler T,Pfister D

    更新日期:2019-04-01 00:00:00

  • Pioneering the trail of cancer immunotherapy.

    abstract::The annual conference of the International Society for Biological Therapy of Cancer (iSBTc), recently renamed the Society for Immunotherapy of Cancer (SITC), provides clinicians and scientists with a uniquely broad yet focused view of the growing field of tumor immunology and cancer immunotherapy. In this time of exci...

    journal_title:Expert review of anticancer therapy

    pub_type:

    doi:10.1586/era.10.229

    authors: Kotlan B,Balwit JM

    更新日期:2011-03-01 00:00:00

  • Systemic treatment of vulvar cancer.

    abstract::Squamous cell carcinoma of the vulva is a rare disease, accounting for approximately 5% of cancers of the female genital tract. Standard therapy for early-stage vulvar cancer mainly comprises of surgery of the vulva and groins. In locally advanced or metastatic vulvar cancer, neoadjuvant or definitive chemoradiation i...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2015.1037837

    authors: Mahner S,Prieske K,Grimm D,Trillsch F,Prieske S,von Amsberg G,Petersen C,Mueller V,Jaenicke F,Woelber L

    更新日期:2015-06-01 00:00:00

  • Medical approaches to non-melanoma skin cancer.

    abstract::Medical therapy represents an alternative treatment approach that can be considered for some forms of non-melanoma skin cancer (NMSC). In selected cases, topical treatments are preferable to invasive procedures, especially in the case of multifocal lesions, unclear lesion edges, risk of keloids, surgical risk factors ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.856759

    authors: Micali G,Lacarrubba F,Bhatt K,Nasca MR

    更新日期:2013-12-01 00:00:00

  • Notch signaling in lung cancer.

    abstract::Lung cancer is the leading cause of cancer-related deaths in the Western world. The lungs can be affected by a number of histologically diverse malignancies. Nonetheless, the vast majority of lung cancers are classified as non-small-cell lung cancer (NSCLC). Despite extensive research on different therapeutic regimens...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.158

    authors: Galluzzo P,Bocchetta M

    更新日期:2011-04-01 00:00:00